< back

Serpiginous choroiditis

Description

Serpiginous choroiditis is a form of choriocapillaritis that affects young men bilaterally. Inflammatory flares that cause ischemia of the choriocapillaris are typical, with a typical appearance of serpentine or serpiginoid atrophy. There is usually no evidence of inflammatory signs such as vitritis, vasculitis or anterior chamber cellularity. The flares leave an atrophic legacy that corresponds to a hypoautofluorescent area in the autofluorescence and complete atrophy of the outer retina in the macular optical coherence tomography (mOCT). In classic serpiginous choroiditis, it is characteristic that the lesion begins in the papillary area and the inflammatory flares originate at the limits of the atrophic area.

To prevent its progression, as in other posterior uveitis, immunosuppressive treatment is often required.

The appearance of neovascular membranes (NVM) at the edges of the lesion is relatively common, and they generally respond well to anti-angiogenic (antiVEGF) treatment.

Comments

Indication

75-year-old male undergoing treatment with antiVEGF (affibecerpt) injections in both eyes for the presence of MNV of years of evolution with good response, orienting at the beginning of the condition as bilateral exudative Age-Related Macular Degeneration (AMD). The fundus shows a peripapillary atrophy with a serpiginoid appearance (figures 1 and 2) with a marked hypoautofluorescence characteristic in both eyes in the autofluorescence (figures 3 and 4). In the Right Eye (RE), a hyperautofluorescent area adjacent to the atrophic area is observed, corresponding to an area of choriocapillaritis activity. The OCT of the RE also detects an active neovascular membrane at the edge of the juxtapapillary atrophy zone with the presence of subfoveal neurosensory detachment (figure 5), whose neovascular bouquet is visualized in the angio-OCT (figure 6). Based on these findings, adjuvant intravitreal treatment with antiVEGF and a dexamethasone device is proposed, as well as initiation of systemic immunosuppressive treatment.